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Complex regional pain syndrome (CRPS) may develop 
the following symptoms: fractures, limb trauma, or lesions 
of the peripheral or central nervous system [1]. CRPS has 
characteristics similar to neuropathic pain (intense burning 
pain, allodynia, and hyperalgesia) and is associated with local 
edema and symptoms suggestive of autonomic involvement 
(altered sweating, skin color, skin temperature in the affected 
limb). Pharmacotherapy is based on individual symptoms and 
it includes steroids, free radical scavengers, opioids, tricyclic 
antidepressants (TCA), sodium blocking agents, and N-methyl-
D-aspartic acid (NMDA) receptor blocking agents. Although the 
pathophysiology of CRPS is not fully understood, it is suggested 
that sympathetically mediated pain is one of the mechanisms of 
CRPS [2].
Therefore, selective sympatholytic blocks (e.g., stellate 
ganglion block) for pain and symptom relief in CRPS patients 
are useful therapeutic options. Alpha-2 adrenergic receptor 
agonist has a centrally mediated reduction of the sympathetic 
nervous system activity [3]. It has been widely used as an 
analgesic adjuvant in perioperative conditions and pain 
therapy. Dexmedetomidine is a more selective α2-adrenergic 
receptor agonist with a shorter elimination half-life compared 
to clonidine. We successfully treated a 43-year-old female with 
acute pain from refractory CRPS type 1 using dexmedetomidine 
after therapy with ketamine, and lidocaine, and with a stellate 
ganglion block had failed. She complained of pallor, and 
presented with dystrophic skin with decreased temperature 
allodynia and hyperalgesia in the left wrist and hand. She took 
gabapentin 600 mg and oxycontin 20 mg daily. However, her 
pain intensity was 8 on a visual analogue scale of 10 (VAS: 0 = “no 
pain” and 10 = “worst pain imaginable”). We controlled her pain 
by continuous cervical epidural block with 0.2 % ropivacaine. 
However, the epidural catheter was removed because of malpo-
sition of the epidural catheter, and then, her pain was treated 
with gabapentin 1,800 mg, oxycodone 40 mg, and amitriptyline 
10 mg daily. In addition, she received a stellate ganglion block 
with 1% lidocaine 7 ml every other day. Her pain intensity 
decreased to 4-5 on the VAS. However, about a month after 
these treatments, her pain intensity suddenly increased to 9 
on the VAS. She complained of extremely sharp, bursting pain 
in her wrist and hand. After SGB with 1% lidocaine, the pain 
intensity decreased to 6-7 on the VAS. However, about one 
hour after SGB, the patient complained of severe pain with a 
VAS score of 9 again. Therefore, we started ketamine therapy 
with a bolus infusion of 10 mg followed by a continuous infusion 
dose of 10 μg/kg/hr. Twenty minutes after the infusion of the 
ketamine, the pain intensity decreased to a VAS score of 6-7, 
but she complained of severe nausea and dizziness; therefore, 
we stopped the ketamine therapy. Furthermore, the infusion of 
lidocaine 200 mg for 15 minutes did not resolve this situation. 
SGB with 1% lidocaine was effective in decreasing the pain, 
but its effect was limited due to the duration of lidocaine. We 
presumed that sympatholysis might be useful for relief of her 
symptoms. Dexmedetomidine reduces the sympathetic nervous 
system activity and is useful in diminishing catecholamine 
release through its sympatholytic properties [3]. Therefore, we 
infused dexmedetomidine at a loading dose of 0.5 μg/kg over 
15 minutes and a continuous infusion dose of 0.2 μg/kg/hr for 3 
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hours. After infusion of dexmedetomidine, her pain decreased 
to a VAS score of 2 without any side effects such as bradycardia 
or hypotension. This effect persisted for three days. After three 
days, she complained of pain with a VAS score of 5-7 again. 
The patient received an infusion of dexmedetomidine again, 
and her VAS score decreased to 2-3 for 4 days. One week later, 
she received a spinal cord stimulator, and then, her pain was 
maintained at a VAS score of 2-3 at the three month follow up.
Central nervous system activation of postsynaptic α2A 
adrenergic receptors results in the inhibition of sympathetic 
activity [3]. Thus, alpha-2 adrenergic receptor agonist has the 
potential therapeutic properties to treat CRPS pain by pre-
venting sympatho-afferent coupling and decreasing sym  pathetic 
outflow. In a previous report, a single shot of dexmedetomidine 
as adjuvant therapy for ketamine was effective in controlling 
acute pain from CRPS [4]. However, ketamine cannot be a 
feasible option because of the side effects such as blurred 
vision, drowsiness, nausea, and vomiting. In this case, the 
patient refused ketamine therapy because of severe nausea and 
drowsiness. However, infusion of dexmedetomidine alone was 
effective in controlling acute pain from CRPS.
Although the elimination half-life of dexmedetomidine 
is short (2-3 hours), the analgesic-sparing effect of 
dexmedetomidine administered intraoperatively lasts up to 
24 to 48 hours after surgery [5]. In this case, pain from CRPS 
significantly decreased for 3-4 days after the infusion of 
dexmedetomidine. The mechanism for the dexmedetomidine 
prolonged analgesic effect in this patient is not well understood 
and further research is needed.
In conclusion, dexmedetomidine may be an alternative 
therapeutic option for the treatment of acute pain from CRPS 
when other treatments fail. Further research is needed to define 
its role in managing chronic pain conditions like CRPS.
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